{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:56:49Z","timestamp":1791014209599,"version":"4.1.0"},"reference-count":51,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,7,15]]},"abstract":"<jats:p>Myasthenia gravis (MG) is associated with ectopic germinal centers in the thymus. Thymectomy and glucocorticoids are the main treatments but they induce operative risks and side effects, respectively. The aim of this study was to propose new therapies more efficient for MG. We hypothesized that molecules dysregulated in MG thymus and normalized by glucocorticoids may play a key role in thymic pathogenesis. Using gene chip analysis, we identified 88 genes complying with these criteria, the most remarkable being the B-cell chemoattractant (CXCL13). Its expression was increased in thymus and sera of glucocorticoid-untreated patients and decreased in response to treatment in correlation with clinical improvement. Normal B cells were actively chemoattracted by thymic extracts from glucocorticoid-untreated patients, an effect inhibited by anti-CXCL13 antibodies. In the thymus, CXCL13 was preferentially produced by epithelial cells and overproduced by epithelial cells from MG patients. Altogether, our results suggest that a high CXCL13 production by epithelial cells could be responsible for germinal center formation in MG thymus. Furthermore, they show that this gene is a main target of corticotherapy. Thus, new therapies targeting CXCL13 could be of interest for MG and other autoimmune diseases characterized by ectopic germinal center formation.<\/jats:p>","DOI":"10.1182\/blood-2005-06-2383","type":"journal-article","created":{"date-parts":[[2006,3,17]],"date-time":"2006-03-17T01:34:30Z","timestamp":1142559270000},"page":"432-440","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":152,"title":["The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis"],"prefix":"10.1182","volume":"108","author":[{"given":"Amel","family":"Meraouna","sequence":"first","affiliation":[{"name":"From Centre National de la Recherche Scientifique\u2013Unite\u0301 mixte de recherche CNRS-UMR 8162, Institut Paris-Sud Cytokines (IPSC), Universite\u0301 Paris XI, Ho\u0302pital Marie Lannelongue, Le Plessis-Robinson, France; and the Department of Neurology, Ulleval University Hospital, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Cizeron-Clairac","sequence":"additional","affiliation":[{"name":"From Centre National de la Recherche Scientifique\u2013Unite\u0301 mixte de recherche CNRS-UMR 8162, Institut Paris-Sud Cytokines (IPSC), Universite\u0301 Paris XI, Ho\u0302pital Marie Lannelongue, Le Plessis-Robinson, France; and the Department of Neurology, Ulleval University Hospital, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozen Le","family":"Panse","sequence":"additional","affiliation":[{"name":"From Centre National de la Recherche Scientifique\u2013Unite\u0301 mixte de recherche CNRS-UMR 8162, Institut Paris-Sud Cytokines (IPSC), Universite\u0301 Paris XI, Ho\u0302pital Marie Lannelongue, Le Plessis-Robinson, France; and the Department of Neurology, Ulleval University Hospital, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacky","family":"Bismuth","sequence":"additional","affiliation":[{"name":"From Centre National de la Recherche Scientifique\u2013Unite\u0301 mixte de recherche CNRS-UMR 8162, Institut Paris-Sud Cytokines (IPSC), Universite\u0301 Paris XI, Ho\u0302pital Marie Lannelongue, Le Plessis-Robinson, France; and the Department of Neurology, Ulleval University Hospital, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Truffault","sequence":"additional","affiliation":[{"name":"From Centre National de la Recherche Scientifique\u2013Unite\u0301 mixte de recherche CNRS-UMR 8162, Institut Paris-Sud Cytokines (IPSC), Universite\u0301 Paris XI, Ho\u0302pital Marie Lannelongue, Le Plessis-Robinson, France; and the Department of Neurology, Ulleval University Hospital, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Tallaksen","sequence":"additional","affiliation":[{"name":"From Centre National de la Recherche Scientifique\u2013Unite\u0301 mixte de recherche CNRS-UMR 8162, Institut Paris-Sud Cytokines (IPSC), Universite\u0301 Paris XI, Ho\u0302pital Marie Lannelongue, Le Plessis-Robinson, France; and the Department of Neurology, Ulleval University Hospital, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Berrih-Aknin","sequence":"additional","affiliation":[{"name":"From Centre National de la Recherche Scientifique\u2013Unite\u0301 mixte de recherche CNRS-UMR 8162, Institut Paris-Sud Cytokines (IPSC), Universite\u0301 Paris XI, Ho\u0302pital Marie Lannelongue, Le Plessis-Robinson, France; and the Department of Neurology, Ulleval University Hospital, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111912420936000_REF1","doi-asserted-by":"crossref","unstructured":"Engel AG. Myasthenia gravis and myasthenic syndromes. Ann Neurol. 1984;16: 519-534.","DOI":"10.1002\/ana.410160502"},{"key":"2019111912420936000_REF2","doi-asserted-by":"crossref","unstructured":"Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330: 1797-1810.","DOI":"10.1056\/NEJM199406233302507"},{"key":"2019111912420936000_REF3","doi-asserted-by":"crossref","unstructured":"Lindstrom J, Shelton D, Fujii Y. Myasthenia gravis. Adv Immunol. 1988;42: 233-284.","DOI":"10.1016\/S0065-2776(08)60847-0"},{"key":"2019111912420936000_REF4","doi-asserted-by":"crossref","unstructured":"Levinson AI, Wheatley LM. The thymus and the pathogenesis of myasthenia gravis. Clin Immunol Immunopathol. 1996;78: 1-5.","DOI":"10.1006\/clin.1996.0001"},{"key":"2019111912420936000_REF5","doi-asserted-by":"crossref","unstructured":"MacLennan IC. Germinal centers. Annu Rev Immunol. 1994;12: 117-139.","DOI":"10.1146\/annurev.iy.12.040194.001001"},{"key":"2019111912420936000_REF6","doi-asserted-by":"crossref","unstructured":"Toellner KM, Gulbranson-Judge A, Taylor DR, Sze DM, MacLennan IC. Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation. J Exp Med. 1996;183: 2303-2312.","DOI":"10.1084\/jem.183.5.2303"},{"key":"2019111912420936000_REF7","doi-asserted-by":"crossref","unstructured":"Randen I, Mellbye OJ, Forre O, Natvig JB. The identification of germinal centres and follicular dendritic cell networks in rheumatoid synovial tissue. Scand J Immunol. 1995;41: 481-486.","DOI":"10.1111\/j.1365-3083.1995.tb03596.x"},{"key":"2019111912420936000_","doi-asserted-by":"crossref","unstructured":"Salomonsson S, Jonsson MV, Skarstein K, et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum. 2003;48: 3187-3201.","DOI":"10.1002\/art.11311"},{"key":"2019111912420936000_REF9","doi-asserted-by":"crossref","unstructured":"Knecht H, Saremaslani P, Hedinger C. Immunohistological findings in Hashimoto's thyroiditis, focal lymphocytic thyroiditis and thyroiditis de Quervain: comparative study. Virchows Arch A Pathol Anat Histol. 1981;393: 215-231.","DOI":"10.1007\/BF00431078"},{"key":"2019111912420936000_REF10","doi-asserted-by":"crossref","unstructured":"Leprince C, Cohen-Kaminsky S, Berrih-Aknin S, et al. Thymic B cells from myasthenia gravis patients are activated B cells: phenotypic and functional analysis. J Immunol. 1990;145: 2115-2122.","DOI":"10.4049\/jimmunol.145.7.2115"},{"key":"2019111912420936000_REF11","doi-asserted-by":"crossref","unstructured":"Papatestas AE, Genkins G, Kornfeld P, et al. Effects of thymectomy in myasthenia gravis. Ann Surg. 1987;206: 79-88.","DOI":"10.1097\/00000658-198707000-00013"},{"key":"2019111912420936000_REF12","doi-asserted-by":"crossref","unstructured":"Aissaoui A, Klingel-Schmitt I, Couderc J, et al. Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis. Ann Neurol. 1999;46: 559-567.","DOI":"10.1002\/1531-8249(199910)46:4<559::AID-ANA3>3.0.CO;2-S"},{"key":"2019111912420936000_REF13","unstructured":"Younger DS, Raksadawan N. Medical therapies in myasthenia gravis. Chest Surg Clin N Am. 2001;11: 329-336."},{"key":"2019111912420936000_REF14","doi-asserted-by":"crossref","unstructured":"Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology. 2003;61: 1652-1661.","DOI":"10.1212\/01.WNL.0000098887.24618.A0"},{"key":"2019111912420936000_REF15","doi-asserted-by":"crossref","unstructured":"Warmolts JR, Engel WK. Benefit from alternate-day prednisone in myasthenia gravis. N Engl J Med. 1972;286: 17-20.","DOI":"10.1056\/NEJM197201062860104"},{"key":"2019111912420936000_REF16","doi-asserted-by":"crossref","unstructured":"Baraka A. Anaesthesia and myasthenia gravis. Can J Anaesth. 1992;39: 476-486.","DOI":"10.1007\/BF03008713"},{"key":"2019111912420936000_REF17","doi-asserted-by":"crossref","unstructured":"Chevalley C, Spiliopoulos A, de Perrot M, Tschopp JM, Licker M. Perioperative medical management and outcome following thymectomy for myasthenia gravis. Can J Anaesth. 2001;48: 446-451.","DOI":"10.1007\/BF03028306"},{"key":"2019111912420936000_REF18","doi-asserted-by":"crossref","unstructured":"Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science. 1999;286: 2098-2102.","DOI":"10.1126\/science.286.5447.2098"},{"key":"2019111912420936000_","doi-asserted-by":"crossref","unstructured":"Muller G, Hopken UE, Lipp M. The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol Rev. 2003;195: 117-135.","DOI":"10.1034\/j.1600-065X.2003.00073.x"},{"key":"2019111912420936000_REF20","doi-asserted-by":"crossref","unstructured":"Allen CD, Ansel KM, Low C, et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol. 2004;5: 943-952.","DOI":"10.1038\/ni1100"},{"key":"2019111912420936000_REF21","doi-asserted-by":"crossref","unstructured":"Jaretzki A III, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards: Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55: 16-23.","DOI":"10.1212\/WNL.55.1.16"},{"key":"2019111912420936000_REF22","doi-asserted-by":"crossref","unstructured":"Berrih S, Arenzana-Seisdedos F, Cohen S, Devos R, Charron D, Virelizier JL. Interferon-gamma modulates HLA class II antigen expression on cultured human thymic epithelial cells. J Immunol. 1985;135: 1165-1171.","DOI":"10.4049\/jimmunol.135.2.1165"},{"key":"2019111912420936000_REF23","doi-asserted-by":"crossref","unstructured":"Wakkach A, Poea S, Chastre E, et al. Establishment of a human thymic myoid cell line: phenotypic and functional characteristics. Am J Pathol. 1999;155: 1229-1240.","DOI":"10.1016\/S0002-9440(10)65225-X"},{"key":"2019111912420936000_REF24","doi-asserted-by":"crossref","unstructured":"Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98: 5116-5121.","DOI":"10.1073\/pnas.091062498"},{"key":"2019111912420936000_REF25","doi-asserted-by":"crossref","unstructured":"Poea-Guyon S, Christadoss P, Le Panse R, et al. Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol. 2005;174: 5941-5949.","DOI":"10.4049\/jimmunol.174.10.5941"},{"key":"2019111912420936000_REF26","doi-asserted-by":"crossref","unstructured":"Nancy P, Berrih-Aknin S. Differential estrogen receptor expression in autoimmune myasthenia gravis. Endocrinology. 2005;146: 2345-2353.","DOI":"10.1210\/en.2004-1003"},{"key":"2019111912420936000_REF27","doi-asserted-by":"crossref","unstructured":"Fearon DT, Wong WW. Complement ligand-receptor interactions that mediate biological responses. Annu Rev Immunol. 1983;1: 243-271.","DOI":"10.1146\/annurev.iy.01.040183.001331"},{"key":"2019111912420936000_REF28","doi-asserted-by":"crossref","unstructured":"Melchers F, Rolink AG, Schaniel C. The role of chemokines in regulating cell migration during humoral immune responses. Cell. 1999;99: 351-354.","DOI":"10.1016\/S0092-8674(00)81521-4"},{"key":"2019111912420936000_REF29","doi-asserted-by":"crossref","unstructured":"Bowen MB, Butch AW, Parvin CA, Levine A, Nahm MH. Germinal center T cells are distinct helper-inducer T cells. Hum Immunol. 1991;31: 67-75.","DOI":"10.1016\/0198-8859(91)90050-J"},{"key":"2019111912420936000_REF30","doi-asserted-by":"crossref","unstructured":"Kim CH, Lim HW, Kim JR, Rott L, Hillsamer P, Butcher EC. Unique gene expression program of human germinal center T helper cells. Blood. 2004;104: 1952-1960.","DOI":"10.1182\/blood-2004-03-1206"},{"key":"2019111912420936000_REF31","doi-asserted-by":"crossref","unstructured":"Gunn MD, Ngo VN, Ansel KM, Ekland EH, Cyster JG, Williams LT. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature. 1998;391: 799-803.","DOI":"10.1038\/35876"},{"key":"2019111912420936000_REF32","doi-asserted-by":"crossref","unstructured":"Fukuoka M, Ogino Y, Sato H, et al. RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol). Br J Dermatol. 1998;138: 63-70.","DOI":"10.1046\/j.1365-2133.1998.02027.x"},{"key":"2019111912420936000_REF33","doi-asserted-by":"crossref","unstructured":"Lamkhioued B, Renzi PM, Abi-Younes S, et al. Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J Immunol. 1997;159: 4593-4601.","DOI":"10.4049\/jimmunol.159.9.4593"},{"key":"2019111912420936000_REF34","doi-asserted-by":"crossref","unstructured":"Koch AE, Kunkel SL, Harlow LA, et al. Macrophage inflammatory protein-1 alpha: a novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest. 1994;93: 921-928.","DOI":"10.1172\/JCI117097"},{"key":"2019111912420936000_","doi-asserted-by":"crossref","unstructured":"Harigai M, Hara M, Yoshimura T, Leonard EJ, Inoue K, Kashiwazaki S. Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol. 1993;69: 83-91.","DOI":"10.1006\/clin.1993.1153"},{"key":"2019111912420936000_","doi-asserted-by":"crossref","unstructured":"Robinson E, Keystone EC, Schall TJ, Gillett N, Fish EN. Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells. Clin Exp Immunol. 1995;101: 398-407.","DOI":"10.1111\/j.1365-2249.1995.tb03126.x"},{"key":"2019111912420936000_REF37","doi-asserted-by":"crossref","unstructured":"Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest. 1998;101: 746-754.","DOI":"10.1172\/JCI1422"},{"key":"2019111912420936000_REF38","doi-asserted-by":"crossref","unstructured":"Feferman T, Maiti PK, Berrih-Aknin S, et al. Interferon-induced protein 10 (IP-10) and its receptor CXCR3 are overexpressed in myasthenia gravis: new targets for immunotherapy. J Immunol. 2005;174: 5324-31.","DOI":"10.4049\/jimmunol.174.9.5324"},{"key":"2019111912420936000_REF39","doi-asserted-by":"crossref","unstructured":"Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum. 2005;52: 1534-1544.","DOI":"10.1002\/art.21006"},{"key":"2019111912420936000_REF40","doi-asserted-by":"crossref","unstructured":"Wakkach A, Guyon T, Bruand C, Tzartos S, Cohen-Kaminsky S, Berrih-Aknin S. Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis. J Immunol. 1996;157: 3752-3760.","DOI":"10.4049\/jimmunol.157.8.3752"},{"key":"2019111912420936000_REF41","doi-asserted-by":"crossref","unstructured":"Carlsen HS, Baekkevold ES, Morton HC, Haraldsen G, Brandtzaeg P. Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood. 2004;104: 3021-3027.","DOI":"10.1182\/blood-2004-02-0701"},{"key":"2019111912420936000_REF42","doi-asserted-by":"crossref","unstructured":"Sciacca FL, Ferri C, Veglia F, et al. IL-1 genes in myasthenia gravis: IL-1A -889 polymorphism associated with sex and age of disease onset. J Neuroimmunol. 2002;122: 94-99.","DOI":"10.1016\/S0165-5728(01)00449-0"},{"key":"2019111912420936000_","doi-asserted-by":"crossref","unstructured":"Huang DR, Pirskanen R, Matell G, Lefvert AK. Tumour necrosis factor-alpha polymorphism and secretion in myasthenia gravis. J Neuroimmunol. 1999;94: 165-171.","DOI":"10.1016\/S0165-5728(98)00253-7"},{"key":"2019111912420936000_REF44","doi-asserted-by":"crossref","unstructured":"Skeie GO, Pandey JP, Aarli JA, Gilhus NE. TNFA and TNFB polymorphisms in myasthenia gravis. Arch Neurol. 1999;56: 457-461.","DOI":"10.1001\/archneur.56.4.457"},{"key":"2019111912420936000_REF45","doi-asserted-by":"crossref","unstructured":"Balandina A, Lecart S, Dartevelle P, Saoudi A, Berrih-Aknin S. Functional defect of regulatory CD4+CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood. 2005;105: 735-741.","DOI":"10.1182\/blood-2003-11-3900"},{"key":"2019111912420936000_REF46","doi-asserted-by":"crossref","unstructured":"Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annu Rev Immunol. 2000;18: 309-345.","DOI":"10.1146\/annurev.immunol.18.1.309"},{"key":"2019111912420936000_REF47","doi-asserted-by":"crossref","unstructured":"Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther. 2002;15: 35-50.","DOI":"10.1006\/pupt.2001.0312"},{"key":"2019111912420936000_REF48","doi-asserted-by":"crossref","unstructured":"Stanbury RM, Graham EM. Systemic corticosteroid therapy: side effects and their management. Br J Ophthalmol. 1998;82: 704-708.","DOI":"10.1136\/bjo.82.6.704"},{"key":"2019111912420936000_REF49","doi-asserted-by":"crossref","unstructured":"Ransohoff RM, Bacon KB. Chemokine receptor antagonism as a new therapy for multiple sclerosis. Expert Opin Investig Drugs. 2000;9: 1079-1097.","DOI":"10.1517\/13543784.9.5.1079"},{"key":"2019111912420936000_","doi-asserted-by":"crossref","unstructured":"Proudfoot AE, Power CA, Wells TN. The strategy of blocking the chemokine system to combat disease. Immunol Rev. 2000;177: 246-256.","DOI":"10.1034\/j.1600-065X.2000.17721.x"},{"key":"2019111912420936000_REF51","doi-asserted-by":"crossref","unstructured":"Proudfoot AE, Handel TM, Johnson Z, et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A. 2003;100: 1885-1890.","DOI":"10.1073\/pnas.0334864100"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/108\/2\/432\/470521\/zh801406000432.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/108\/2\/432\/470521\/zh801406000432.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T20:02:42Z","timestamp":1683403362000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/108\/2\/432\/109853\/The-chemokine-CXCL13-is-a-key-molecule-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,15]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,7,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-06-2383","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,15]]}}}